ResMed (ASX:RMD) logged $2.95 in non-GAAP EPS for the fiscal fourth quarter, compared with $2.55 a year ago, a Friday statement showed.
Analysts polled by FactSet expected earnings of $2.89.
For the three months ended June 30, revenue was $1.46 billion versus $1.35 billion previously, the Australia-listed global medical technology and digital health company added. Analysts surveyed by FactSet expected $1.46 billion.
The board declared a quarterly dividend of $0.66 per share, up 10% from the previous quarterly dividend, payable Sept. 24 to shareholders on record as of Aug. 20.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.